Annual D&A
$0.00
-$5.67 M-100.00%
31 December 2023
Summary:
Royalty Pharma annual depreciation & amortization is currently $0.00, with the most recent change of -$5.67 million (-100.00%) on 31 December 2023. During the last 3 years, it has fallen by -$23.00 million (-100.00%). RPRX annual D&A is now -100.00% below its all-time high of $33.27 million, reached on 31 December 2017.RPRX Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly D&A
N/A
30 September 2024
Summary:
Royalty Pharma quarterly depreciation & amortization is not available.RPRX Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM D&A
N/A
30 September 2024
Summary:
Royalty Pharma TTM depreciation & amortization is not available.RPRX TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RPRX Depreciation And Amortization Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -100.0% | - | - |
| 5 y5 years | -100.0% | - | - |
RPRX Depreciation And Amortization High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -100.0% | |||||
| 5 y | 5 years | -100.0% | |||||
| alltime | all time | -100.0% |
Royalty Pharma Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $0.00(-100.0%) | - | - |
| Dec 2022 | $5.67 M(-75.3%) | $0.00(0.0%) | $5.67 M(-50.5%) |
| Sept 2022 | - | $0.00(0.0%) | $11.47 M(-33.6%) |
| June 2022 | - | $0.00(-100.0%) | $17.26 M(-24.9%) |
| Mar 2022 | - | $5.67 M(-2.2%) | $23.00 M(-0.0%) |
| Dec 2021 | $23.00 M(-0.3%) | $5.80 M(0.0%) | $23.00 M(0.0%) |
| Sept 2021 | - | $5.80 M(+1.1%) | $23.00 M(0.0%) |
| June 2021 | - | $5.73 M(+1.1%) | $23.00 M(0.0%) |
| Mar 2021 | - | $5.67 M(-2.2%) | $23.00 M(-0.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $23.06 M(-3.6%) | $5.80 M(0.0%) | $23.06 M(-44.0%) |
| Sept 2020 | - | $5.80 M(+1.1%) | $41.19 M(+78.6%) |
| June 2020 | - | $5.73 M(0.0%) | $23.06 M(0.0%) |
| Mar 2020 | - | $5.73 M(-76.0%) | $23.06 M(-3.6%) |
| Dec 2019 | $23.92 M(-28.1%) | $23.92 M(-294.0%) | $23.92 M(>+9900.0%) |
| Sept 2019 | - | -$12.33 M(-315.1%) | $0.00(-100.0%) |
| June 2019 | - | $5.73 M(-13.1%) | $12.33 M(+86.9%) |
| Mar 2019 | - | $6.60 M | $6.60 M |
| Dec 2018 | $33.27 M(0.0%) | - | - |
| Dec 2017 | $33.27 M | - | - |
FAQ
- What is Royalty Pharma annual depreciation & amortization?
- What is the all time high annual D&A for Royalty Pharma?
- What is the all time high quarterly D&A for Royalty Pharma?
- What is the all time high TTM D&A for Royalty Pharma?
What is Royalty Pharma annual depreciation & amortization?
The current annual D&A of RPRX is $0.00
What is the all time high annual D&A for Royalty Pharma?
Royalty Pharma all-time high annual depreciation & amortization is $33.27 M
What is the all time high quarterly D&A for Royalty Pharma?
Royalty Pharma all-time high quarterly depreciation & amortization is $23.92 M
What is the all time high TTM D&A for Royalty Pharma?
Royalty Pharma all-time high TTM depreciation & amortization is $41.19 M